Phaseline

Targets › G6PC

G6PC (Glucose-6-phosphatase catalytic subunit 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Nov 2026.

Hydrolyzes glucose-6-phosphate to glucose in the endoplasmic reticulum. Forms with the glucose-6-phosphate transporter (SLC37A4/G6PT) the complex responsible for glucose production in the terminal step of glycogenolysis and gluconeogenesis. (UniProt, P35575)

Open in Phaseline: the race on G6PC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ModernaTXmRNA-3745
mRNA therapy encoding glucose-6-phosphatase
G6PCPhase 1Glycogen Storage DiseaseNov 2026

Conditions

Glycogen Storage Disease (1)

Modalities

other (1)

Companies

ModernaTX (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.